- Home
- KYTX vs ENTA Comparison
KYTX vs ENTA Comparison
Compare KYTX & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYTX
- ENTA
- Stock Information
- Founded
- KYTX 2018
- ENTA 1995
- Country
- KYTX United States
- ENTA United States
- Employees
- KYTX 119
- ENTA N/A
- Industry
- KYTX
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- KYTX
- ENTA Health Care
- Exchange
- KYTX NYSE
- ENTA Nasdaq
- Market Cap
- KYTX 150.0M
- ENTA 160.3M
- IPO Year
- KYTX 2024
- ENTA 2013
- Fundamental
- Price
- KYTX $2.81
- ENTA $7.89
- Analyst Decision
- KYTX Strong Buy
- ENTA Buy
- Analyst Count
- KYTX 5
- ENTA 4
- Target Price
- KYTX $19.00
- ENTA $18.00
- AVG Volume (30 Days)
- KYTX 603.2K
- ENTA 181.3K
- Earning Date
- KYTX 08-11-2025
- ENTA 08-04-2025
- Dividend Yield
- KYTX N/A
- ENTA N/A
- EPS Growth
- KYTX N/A
- ENTA N/A
- EPS
- KYTX N/A
- ENTA N/A
- Revenue
- KYTX N/A
- ENTA $64,462,999.00
- Revenue This Year
- KYTX N/A
- ENTA N/A
- Revenue Next Year
- KYTX N/A
- ENTA $0.48
- P/E Ratio
- KYTX N/A
- ENTA N/A
- Revenue Growth
- KYTX N/A
- ENTA N/A
- 52 Week Low
- KYTX $1.78
- ENTA $4.09
- 52 Week High
- KYTX $11.40
- ENTA $17.24
- Technical
- Relative Strength Index (RSI)
- KYTX 46.72
- ENTA 67.33
- Support Level
- KYTX $2.71
- ENTA $6.95
- Resistance Level
- KYTX $3.75
- ENTA $8.23
- Average True Range (ATR)
- KYTX 0.31
- ENTA 0.40
- MACD
- KYTX -0.08
- ENTA 0.00
- Stochastic Oscillator
- KYTX 9.62
- ENTA 75.11
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.